COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04053634




Registration number
NCT04053634
Ethics application status
Date submitted
16/07/2019
Date registered
12/08/2019
Date last updated
10/11/2020

Titles & IDs
Public title
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Scientific title
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
Secondary ID [1] 0 0
2019-001800-39
Secondary ID [2] 0 0
D3251C00014
Universal Trial Number (UTN)
Trial acronym
RESOLUTE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Benralizumab
Other interventions - Placebo

Experimental: Benralizumab - Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks

Placebo Comparator: Placebo - Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks


Other interventions: Benralizumab
Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

Other interventions: Placebo
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized rate of moderate or severe COPD exacerbations - Moderate or severe COPD exacerbation is defined by symptomatic worsening of COPD requiring:
Use of systemic corticosteroids for at least 3 days; and/or
Use of antibiotics; and/or
An inpatient hospitalization or death due to COPD
Timepoint [1] 0 0
Over first 56 weeks
Secondary outcome [1] 0 0
Annualized rate of severe COPD exacerbations - A severe COPD exacerbation is defined by symptomatic worsening of COPD requiring an inpatient hospitalization or results in death due to COPD
Timepoint [1] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [2] 0 0
Annualized rate of COPD exacerbations that are associated with an emergency room/emergency department visit or a hospitalization
Timepoint [2] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [3] 0 0
Time to first COPD exacerbation
Timepoint [3] 0 0
During first 56 weeks
Secondary outcome [4] 0 0
Change from baseline in SGRQ total and domain scores - St. George's Respiratory Questionnaire (SGRQ)
Timepoint [4] 0 0
up to 56 weeks
Secondary outcome [5] 0 0
Change from baseline in E-RS:COPD total and domain scores - Evaluating Respiratory Symptoms in COPD (E-RS:COPD)
Timepoint [5] 0 0
up to 56 weeks
Secondary outcome [6] 0 0
Change from baseline in pre-dose/pre-bronchodilator FEV1 - FEV1 is the Forced expiratory volume in one second at study site
Timepoint [6] 0 0
up to 56 weeks
Secondary outcome [7] 0 0
All cause and respiratory-related mortality rate
Timepoint [7] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [8] 0 0
Annual rate of hospitalizations due to COPD
Timepoint [8] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [9] 0 0
Serum benralizumab concentration as a measure of pharmacokinetics
Timepoint [9] 0 0
up to 56 weeks
Secondary outcome [10] 0 0
Anti-drug antibodies (ADA) as a measure of immunogenicity
Timepoint [10] 0 0
up to 56 weeks
Secondary outcome [11] 0 0
Change from baseline in CAT total score - Chronic Obstructive Pulmonary Disease assessment tool (CAT)
Timepoint [11] 0 0
up to 56 weeks
Secondary outcome [12] 0 0
Length of hospital stay
Timepoint [12] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [13] 0 0
ICU (Intensive Care Unit) days
Timepoint [13] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [14] 0 0
Annual rate of hospitalizations and emergency department visits combined
Timepoint [14] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [15] 0 0
Annual rate of unscheduled outpatient visits including unscheduled visits to study sites
Timepoint [15] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [16] 0 0
Annual rate of unscheduled healthcare encounters
Timepoint [16] 0 0
Minimum of 1 year and and average of 2 years

Eligibility
Key inclusion criteria
1. Provision of informed consent

2. Age 40 to 85 years

3. Male and/or female.

4. Current or former smoker with a tobacco history of =10 pack-years.

5. History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC<0.70 and
FEV1 =65% of predicted normal value.

6. Documented history of 2 or more COPD exacerbations that required treatment with
systemic corticosteroids and/or hospitalization within 52 weeks prior to enrollment.

1. Exacerbations treated with antibiotics alone are excluded unless accompanied by
treatment with systemic corticosteroids and/or hospitalization.

2. Hospitalization is defined as an inpatient admission =24 hours

3. Previous exacerbations should be confirmed to have occurred while on stable
triple therapy for COPD.

7. Documented use of triple (ICS/LABA/LAMA) background therapy for COPD throughout the
year (52 weeks) prior to enrollment.

1. ICS in a dose approved for COPD or equivalent to =250 mcg of fluticasone
propionate daily.

2. Total cumulative duration of not being on triple background therapy must not
exceed 2 months.

3. Stable therapy/doses for the last 3 months prior to randomization.

8. Blood eosinophil count =300/µL at screening and documented historical eosinophil count
of =150/µL within 52 weeks of enrollment (or repeated testing during run-in).

9. CAT total score =15 at Visit 1.

10. Negative pregnancy test for females of childbearing potential (WOCBP) at Visit 1.

11. Women of childbearing potential (WOCBP) must agree to use a highly effective method of
birth control from enrollment throughout the study and within 12 weeks after last dose
of IP.

Women not of childbearing potential are defined as women who are either permanently
sterilized or postmenopausal (confirmed by FSH test for women <50 years).
Minimum age
40 Years
Maximum age
85 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Clinically important pulmonary disease other than COPD

2. Current diagnosis of asthma, prior history of asthma or asthma-COPD overlap according
to GINA/GOLD. Childhood history of asthma is allowed and defined as asthma diagnosed
and resolved before the age of 18.

3. Radiological findings of a respiratory disease other than COPD contributing to
respiratory symptoms. Solitary pulmonary nodules without appropriate follow up or
findings of acute infection.

4. Another pulmonary or systemic disease associated with elevated peripheral eosinophil
counts.

5. Any unstable disorder that could affect patient safety, study findings or the
patient's ability to complete the study.

6. Any clinically significant abnormal findings in physical examination, vital signs,
ECG, laboratory tests could affect patient safety, study findings or the patient's
ability to complete the study.

7. Cor pulmonale and/or right ventricular failure.

8. Long-term treatment with oxygen >4.0 L/min and/or oxyhemoglobin saturation <89% while
breathing supplemental oxygen.

9. Use of any non-invasive positive pressure ventilation device (NIPPV). Note: use of
CPAP for Sleep Apnea Syndrome is allowed.

10. Known immunodeficiency disorder, including positive HIV-1/2 testing.

11. Active liver disease. Chronic stable hepatitis B and C (including positive HBsAg or
hepatitis C antibody testing), or other stable chronic liver disease are acceptable.

12. ALT or AST =3 times the upper limit of normal, confirmed by repeated testing during
the run-in period.

13. Helminth parasitic infection within 24 weeks prior to enrollment, not treated or
failed to respond to standard of care therapy.

14. Alcohol or drug abuse within the past year, which may compromise the study data.

15. Malignancy, current or within the past 5 years, except for adequately treated non
invasive basal cell and squamous cell carcinoma of the skin and cervical
carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1.
Suspected malignancy or undefined neoplasms.

16. Evidence of active tuberculosis, as judged by investigator. Patients with a recent
(within 2 years) first-time or newly positive PPD or Quantiferon test need to complete
an appropriate course of treatment before enrollment. Evaluation will be according to
the local standard of care.

17. Participation, or planned participation, in intensive COPD rehabilitation program
(maintenance phase of a rehabilitation is allowed).

18. History of surgical or endoscopic lung volume reduction within the 6 months prior to
enrollment. History of partial or total lung resection (single lobe or segmentectomy
is acceptable).

19. Scheduled major surgical procedure during the study. Minor elective procedures are
allowed.

20. History of anaphylaxis to benralizumab or any other biologic therapy.

21. Receipt of blood products or immunoglobulins within 30 days prior to randomization.

22. Receipt of any marketed or investigational biologic product within 4 months or 5
half-lives prior to randomization, whichever is longer.

23. Receipt of live attenuated vaccines 30 days prior to randomization.

24. Chronic use of immunosuppressive medication or expected need for chronic use during
the study.

25. Chronic use of antibiotics if duration of treatment is <9 months prior to
randomization. Chronic macrolide or other antibiotic therapy is allowed provided the
patient has been on stable dose/regimen for =9 months prior to randomization and has
had =2 COPD exacerbations while on stable therapy.

26. Receipt of any investigational non-biologic product within 30 days or 5 half-lives
prior to enrollment.

27. Receipt of benralizumab within 12 months prior to enrollment.

28. Known history of allergy or reaction to any component of the IP formulation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Caringbah
Recruitment hospital [2] 0 0
Research Site - Prahran
Recruitment hospital [3] 0 0
Research Site - South Brisbane
Recruitment hospital [4] 0 0
Research Site - Spearwood
Recruitment postcode(s) [1] 0 0
2229 - Caringbah
Recruitment postcode(s) [2] 0 0
3004 - Prahran
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
6163 - Spearwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Kentucky
Country [14] 0 0
United States of America
State/province [14] 0 0
Louisiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
Nebraska
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Oregon
Country [27] 0 0
United States of America
State/province [27] 0 0
Pennsylvania
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
South Dakota
Country [30] 0 0
United States of America
State/province [30] 0 0
Tennessee
Country [31] 0 0
United States of America
State/province [31] 0 0
Texas
Country [32] 0 0
United States of America
State/province [32] 0 0
Utah
Country [33] 0 0
United States of America
State/province [33] 0 0
Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Washington
Country [35] 0 0
United States of America
State/province [35] 0 0
West Virginia
Country [36] 0 0
United States of America
State/province [36] 0 0
Wisconsin
Country [37] 0 0
Argentina
State/province [37] 0 0
Buenos Aires
Country [38] 0 0
Argentina
State/province [38] 0 0
Caba
Country [39] 0 0
Argentina
State/province [39] 0 0
Ciudad Autónoma de Buenos Aire
Country [40] 0 0
Argentina
State/province [40] 0 0
Córdoba
Country [41] 0 0
Argentina
State/province [41] 0 0
Florencio Varela
Country [42] 0 0
Argentina
State/province [42] 0 0
Florida
Country [43] 0 0
Argentina
State/province [43] 0 0
Mar del Plata
Country [44] 0 0
Argentina
State/province [44] 0 0
Mendoza
Country [45] 0 0
Argentina
State/province [45] 0 0
San Fernando
Country [46] 0 0
Argentina
State/province [46] 0 0
Tucumán
Country [47] 0 0
Austria
State/province [47] 0 0
Bludenz
Country [48] 0 0
Austria
State/province [48] 0 0
Feldbach
Country [49] 0 0
Austria
State/province [49] 0 0
Grieskirchen
Country [50] 0 0
Austria
State/province [50] 0 0
Linz
Country [51] 0 0
Austria
State/province [51] 0 0
Thalheim
Country [52] 0 0
Belgium
State/province [52] 0 0
Edegem
Country [53] 0 0
Belgium
State/province [53] 0 0
Erpent
Country [54] 0 0
Brazil
State/province [54] 0 0
Botucatu
Country [55] 0 0
Brazil
State/province [55] 0 0
Maringa
Country [56] 0 0
Brazil
State/province [56] 0 0
Porto Alegre
Country [57] 0 0
Brazil
State/province [57] 0 0
Santo Andre
Country [58] 0 0
Brazil
State/province [58] 0 0
Sao Bernardo do Campo
Country [59] 0 0
Brazil
State/province [59] 0 0
Sao Paulo
Country [60] 0 0
Brazil
State/province [60] 0 0
Sorocaba
Country [61] 0 0
Brazil
State/province [61] 0 0
Uberlandia
Country [62] 0 0
Canada
State/province [62] 0 0
British Columbia
Country [63] 0 0
Canada
State/province [63] 0 0
Nova Scotia
Country [64] 0 0
Canada
State/province [64] 0 0
Ontario
Country [65] 0 0
Canada
State/province [65] 0 0
Quebec
Country [66] 0 0
Canada
State/province [66] 0 0
Saskatchewan
Country [67] 0 0
Chile
State/province [67] 0 0
Curico
Country [68] 0 0
Chile
State/province [68] 0 0
Quillota
Country [69] 0 0
Chile
State/province [69] 0 0
Santiago
Country [70] 0 0
Chile
State/province [70] 0 0
Talca
Country [71] 0 0
Chile
State/province [71] 0 0
Viña del Mar
Country [72] 0 0
Colombia
State/province [72] 0 0
Barranquilla
Country [73] 0 0
Colombia
State/province [73] 0 0
Cali
Country [74] 0 0
Colombia
State/province [74] 0 0
Floridablanca
Country [75] 0 0
Colombia
State/province [75] 0 0
Medellin
Country [76] 0 0
Colombia
State/province [76] 0 0
Pereira
Country [77] 0 0
Czechia
State/province [77] 0 0
Brandys nad Labem
Country [78] 0 0
Czechia
State/province [78] 0 0
Jindrichuv Hradec
Country [79] 0 0
Czechia
State/province [79] 0 0
Ostrava
Country [80] 0 0
Czechia
State/province [80] 0 0
Praha 4
Country [81] 0 0
Czechia
State/province [81] 0 0
Rokycany
Country [82] 0 0
Czechia
State/province [82] 0 0
Teplice
Country [83] 0 0
Czechia
State/province [83] 0 0
Varnsdorf
Country [84] 0 0
Denmark
State/province [84] 0 0
Hvidovre
Country [85] 0 0
Denmark
State/province [85] 0 0
København NV
Country [86] 0 0
Denmark
State/province [86] 0 0
Odense C
Country [87] 0 0
Denmark
State/province [87] 0 0
Roskilde
Country [88] 0 0
Denmark
State/province [88] 0 0
Vejle
Country [89] 0 0
Denmark
State/province [89] 0 0
Ålborg
Country [90] 0 0
Germany
State/province [90] 0 0
Aachen
Country [91] 0 0
Germany
State/province [91] 0 0
Bamberg
Country [92] 0 0
Germany
State/province [92] 0 0
Berlin
Country [93] 0 0
Germany
State/province [93] 0 0
Darmstadt
Country [94] 0 0
Germany
State/province [94] 0 0
Hamburg
Country [95] 0 0
Germany
State/province [95] 0 0
Hannover
Country [96] 0 0
Germany
State/province [96] 0 0
Koblenz
Country [97] 0 0
Germany
State/province [97] 0 0
Köln
Country [98] 0 0
Germany
State/province [98] 0 0
Leipzig
Country [99] 0 0
Germany
State/province [99] 0 0
Neu-Isenburg
Country [100] 0 0
Germany
State/province [100] 0 0
Rheine
Country [101] 0 0
Germany
State/province [101] 0 0
Warendorf
Country [102] 0 0
Greece
State/province [102] 0 0
Athens
Country [103] 0 0
Greece
State/province [103] 0 0
Heraklion
Country [104] 0 0
Greece
State/province [104] 0 0
Ioannina
Country [105] 0 0
Greece
State/province [105] 0 0
Thessaloniki
Country [106] 0 0
Hungary
State/province [106] 0 0
Balassagyarmat
Country [107] 0 0
Hungary
State/province [107] 0 0
Edelény
Country [108] 0 0
Hungary
State/province [108] 0 0
Gödöllo
Country [109] 0 0
Hungary
State/province [109] 0 0
Hajdúnánás
Country [110] 0 0
Hungary
State/province [110] 0 0
Komárom
Country [111] 0 0
Hungary
State/province [111] 0 0
Pécs
Country [112] 0 0
Hungary
State/province [112] 0 0
Siófok
Country [113] 0 0
Hungary
State/province [113] 0 0
Szeged
Country [114] 0 0
Hungary
State/province [114] 0 0
Százhalombatta
Country [115] 0 0
Hungary
State/province [115] 0 0
Törökbálint
Country [116] 0 0
Italy
State/province [116] 0 0
Catanzaro
Country [117] 0 0
Italy
State/province [117] 0 0
Cona
Country [118] 0 0
Italy
State/province [118] 0 0
Genova
Country [119] 0 0
Italy
State/province [119] 0 0
Milaan
Country [120] 0 0
Italy
State/province [120] 0 0
Milano
Country [121] 0 0
Italy
State/province [121] 0 0
Napoli
Country [122] 0 0
Italy
State/province [122] 0 0
Reggio Emilia
Country [123] 0 0
Italy
State/province [123] 0 0
Roma
Country [124] 0 0
Japan
State/province [124] 0 0
Chuo-ku
Country [125] 0 0
Japan
State/province [125] 0 0
Fukuoka-shi
Country [126] 0 0
Japan
State/province [126] 0 0
Himeji-shi
Country [127] 0 0
Japan
State/province [127] 0 0
Hitachinaka-shi
Country [128] 0 0
Japan
State/province [128] 0 0
Joyo-shi
Country [129] 0 0
Japan
State/province [129] 0 0
Kasuga-shi
Country [130] 0 0
Japan
State/province [130] 0 0
Kawachinagano-shi
Country [131] 0 0
Japan
State/province [131] 0 0
Kishiwada-shi
Country [132] 0 0
Japan
State/province [132] 0 0
Kobe-shi
Country [133] 0 0
Japan
State/province [133] 0 0
Koto-ku
Country [134] 0 0
Japan
State/province [134] 0 0
Kure-shi
Country [135] 0 0
Japan
State/province [135] 0 0
Matsusaka-shi
Country [136] 0 0
Japan
State/province [136] 0 0
Meguro-ku
Country [137] 0 0
Japan
State/province [137] 0 0
Mizunami-shi
Country [138] 0 0
Japan
State/province [138] 0 0
Nagaoka-shi
Country [139] 0 0
Japan
State/province [139] 0 0
Nagoya-shi
Country [140] 0 0
Japan
State/province [140] 0 0
Nishinomiya-shi
Country [141] 0 0
Japan
State/province [141] 0 0
Okayama-shi
Country [142] 0 0
Japan
State/province [142] 0 0
Osaka-shi
Country [143] 0 0
Japan
State/province [143] 0 0
Sagamihara-shi
Country [144] 0 0
Japan
State/province [144] 0 0
Sakai-shi
Country [145] 0 0
Japan
State/province [145] 0 0
Sakaide-shi
Country [146] 0 0
Japan
State/province [146] 0 0
Seto-shi
Country [147] 0 0
Japan
State/province [147] 0 0
Shinagawa-ku
Country [148] 0 0
Japan
State/province [148] 0 0
Toshima-ku
Country [149] 0 0
Japan
State/province [149] 0 0
Toyonaka-shi
Country [150] 0 0
Japan
State/province [150] 0 0
Ueda-shi
Country [151] 0 0
Japan
State/province [151] 0 0
Yanagawa-shi
Country [152] 0 0
Japan
State/province [152] 0 0
Yokohama-shi
Country [153] 0 0
Korea, Republic of
State/province [153] 0 0
Daegu
Country [154] 0 0
Korea, Republic of
State/province [154] 0 0
Gangwon-do
Country [155] 0 0
Korea, Republic of
State/province [155] 0 0
Jeonju-si
Country [156] 0 0
Korea, Republic of
State/province [156] 0 0
Seoul
Country [157] 0 0
Mexico
State/province [157] 0 0
Guadalajara
Country [158] 0 0
Mexico
State/province [158] 0 0
Mexico
Country [159] 0 0
Netherlands
State/province [159] 0 0
Amersfoort
Country [160] 0 0
Netherlands
State/province [160] 0 0
Breda
Country [161] 0 0
Netherlands
State/province [161] 0 0
Den Haag
Country [162] 0 0
Netherlands
State/province [162] 0 0
Hertogenbosch
Country [163] 0 0
Netherlands
State/province [163] 0 0
Leeuwarden
Country [164] 0 0
New Zealand
State/province [164] 0 0
Auckland
Country [165] 0 0
New Zealand
State/province [165] 0 0
Christchurch
Country [166] 0 0
New Zealand
State/province [166] 0 0
Dunedin
Country [167] 0 0
New Zealand
State/province [167] 0 0
Waikato
Country [168] 0 0
Philippines
State/province [168] 0 0
Cavite City
Country [169] 0 0
Philippines
State/province [169] 0 0
Iloilo City
Country [170] 0 0
Philippines
State/province [170] 0 0
Quezon City
Country [171] 0 0
Poland
State/province [171] 0 0
Bialystok
Country [172] 0 0
Poland
State/province [172] 0 0
Katowice
Country [173] 0 0
Poland
State/province [173] 0 0
Poznan
Country [174] 0 0
Poland
State/province [174] 0 0
Proszowice
Country [175] 0 0
Poland
State/province [175] 0 0
Rzeszów
Country [176] 0 0
Poland
State/province [176] 0 0
Wielun
Country [177] 0 0
Poland
State/province [177] 0 0
Lódz
Country [178] 0 0
Spain
State/province [178] 0 0
Barcelona
Country [179] 0 0
Spain
State/province [179] 0 0
Hospitalet de Llobregat(Barcel
Country [180] 0 0
Spain
State/province [180] 0 0
Laredo
Country [181] 0 0
Spain
State/province [181] 0 0
Madrid
Country [182] 0 0
Spain
State/province [182] 0 0
Malaga
Country [183] 0 0
Sweden
State/province [183] 0 0
Go¨teborg
Country [184] 0 0
Sweden
State/province [184] 0 0
Helsingborg
Country [185] 0 0
Sweden
State/province [185] 0 0
Lund
Country [186] 0 0
Sweden
State/province [186] 0 0
Stockholm
Country [187] 0 0
Turkey
State/province [187] 0 0
Adana
Country [188] 0 0
Turkey
State/province [188] 0 0
Ankara
Country [189] 0 0
Turkey
State/province [189] 0 0
Antalya
Country [190] 0 0
Turkey
State/province [190] 0 0
Istanbul
Country [191] 0 0
Turkey
State/province [191] 0 0
Mersin
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Birmingham
Country [193] 0 0
United Kingdom
State/province [193] 0 0
Bradford
Country [194] 0 0
United Kingdom
State/province [194] 0 0
Chertsey
Country [195] 0 0
United Kingdom
State/province [195] 0 0
Cottingham
Country [196] 0 0
United Kingdom
State/province [196] 0 0
Larbert
Country [197] 0 0
United Kingdom
State/province [197] 0 0
Leicester
Country [198] 0 0
United Kingdom
State/province [198] 0 0
Newcastle-upon-Tyne
Country [199] 0 0
United Kingdom
State/province [199] 0 0
Oxford
Country [200] 0 0
United Kingdom
State/province [200] 0 0
Southampton
Country [201] 0 0
United Kingdom
State/province [201] 0 0
Wishaw

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate
to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral
blood eosinophils (=300/µL).

Eligible patients must have a history of =2 moderate and/or severe COPD exacerbations in the
previous year despite receiving triple (ICS/LABA/LAMA) background therapy. Eligible patients
must also have an elevated blood eosinophil count.

The treatment period will be of variable duration and will continue until the last patient
has the opportunity to complete a minimum of 56 weeks, at which point all patients will
complete the study. The primary endpoint will be analyzed at Week 56.
Trial website
https://clinicaltrials.gov/show/NCT04053634
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gerard Criner, MD
Address 0 0
Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04053634